Flagship Pioneering, Inc. and Pfizer Inc. have partnered to create a new pipeline of innovative medicines with each company investing $50 million upfront to research and develop 10 single-asset programs leveraging Flagship’s ecosystem of more than 40 human health companies and multiple biotechnology platforms. Pfizer will fund and have an option to acquire each selected development program. Flagship and its bioplatform companies will be eligible to receive up to $700 million in milestones ...